News Focus
News Focus
icon url

DewDiligence

11/03/15 9:54 AM

#196776 RE: DewDiligence #196714

SHPG/DYAX—Criteria for CVR to pay $4/sh:

• DX-2930 full approval (not Subpart H accelerated approval) by 12/31/19; and
• No REMS; and
• No black-box warning in FDA label.

H/t @AndyBiotech.